Pharmaceutical executives challenges

The Transformation Challenges Facing Pharmaceutical Executives

Pharmaceutical companies across the globe face unprecedented challenges as revenue streams come under pressure. This is a consequence of pricing pressures caused by healthcare reforms and government austerity measures. At the same time, companies face increased competition and the difficulty of bringing new drugs and products to market. They have to embrace technological innovation and look at cross-industry best practices …

Could Antibodies Provide the Answer to Curing Ebola?

Newly discovered antibody drugs such as ZMAPP could provide a solution to the Ebola epidemic that’s sweeping across the globe. We have known about the capacity of antibodies for modulating the immune system for decades, and there are already hundreds of antibody-based drugs that are used to effectively fight various illnesses such as cancer and autoimmune diseases. ZMAPP has been shown …

Continuous integrated upstream and downstream processes: a viable option for the future of big pharma?

Is a continuous upstream and downstream process a viable option for the future? Integrated upstream and downstream technology seems to be the ‘holy grail’ of what can be expected for the future of biosimilar drug extraction. Industry pharma leaders such as Genzyme, GE Healthcare, and Novo Nordisk and CMO companies such as Gallus and Rentschler are all working on pushing the …

Malaysia’s Premier Biotechnology Park and Ecosystem

Date: 13 March 2014 Time: 9.00am to 2.30pm Venue: Bio-XCell Biotechnology Park, Nusajaya, Johor, Malaysia              Bio-XCell Biotechnology Park (Bio-XCell) is Malaysia’s premier biotechnology park dedicated to healthcare and industrial biotechnology. The park is strategically located in Nusajaya, within the Iskandar region of Johor, Malaysia.  Bio-XCell offers an environment conducive for the development and manufacturing of biologics, pharmaceuticals, bio-based / …

Signs of validation for investors in cord blood banking – the industry consolidation

Diseases treated with cord blood stem cells have become more and more common nowadays. This is one of the reasons driving the cord blood market from $3.4 to a prospective growth of $14.9B in a span of five years. This is one sign of validation investors look for to invest in the cord blood banking industry. If the cord blood …

Deploying ‘Omics for better cell line development

  Proteomics and genomics have long been used to drive cell line development. It was only recently that the scientific community shunned some light and gave metabolomics some credibility. This, however, does not compare to the decade-long spotlight proteomics and genomics have been given. What's the fuss about metabolomics? It can distinguish differences between concentrations of many different molecules that …

Download report: Key stakeholders share their views about the nutraceuticals industry in Asia

The Nutraceuticals World Asia team recently gathered opinions from pharma, research/academia, consultancy, contract service provider, biotech and some other relevant professionals relating to their geographical market focus in Asia, important nutraceutical strategic areas and challenges they are facing in the nutraceuticals field. Over 91% of those who responded to our survey indicated that they are not currently in the nutraceuticals …

Infographic: Top 10 regions in biotechnology applications

  Based on patent and investment data, Assay Depot has designed a detailed infographic showing the most innovative regions in the world in regards to biotechnology applications. This infographic is a great indicator of future hotspots for drug discovery breakthroughs. Were there any surprises? Are there any regions that didn't make the list? See the full infographic here     …